A new trastuzumab-ageritin-based immunotoxin that specifically kills breast cancer cells

2026-06-20

PRE

Angela Oliver

Nicola Landi

Emanuela Iaccarino

Sara Ragucci

Maria Cantile

Raffaele Ronca

Speranza Annunziata

Giovannina Barisciano

Paolo V. Pedone

Antimo Di Maro *

Annamaria Sandomenico *

Menotti Ruvo

DOI：10.1016/j.ijbiomac.2026.153093

Original

Original request for help

Save

Abstract

En 中文

Antibody-drug conjugates (ADCs) and other similar drug conjugates, constitute a new class of highly effective therapeutic agents, many of which are clinically approved. A subset of ADCs are immunotoxins (ITs) which contain a protein toxin instead of small cytotoxic agents. Several toxins have been investigated, including small proteins from fungi that inhibit protein synthesis by cleaving a phosphodiester bond within the conserved alpha-sarcin loop (SRL) of 23–28S rRNAs.

Keywords:

Ageritin

Immuno-ribotoxin

Trastuzumab

A new trastuzumab-ageritin-based immunotoxin that specifically kills breast cancer cells

Abstract

Journal

Organization

Cited Papers

Citing Papers